Creative Medical Technology Holdings, Inc. (CELZ) stock
CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.53−0.09 (-14.35%)
Close on Nov 13, 2026Market cap $3.48MP/E –Yield –
Creative Medical Technology total assets
Total assets on the balance sheet at the end of each period.
Creative Medical Technology's total assets was $7.28M at Sep 30, 2026. For fiscal 2025 it was $7.81M, up 17.1% from the year before. Over ten years it grew 65.8% a year on average. The highest annual figure on record is $19.19M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.81M | +17.1% |
| FY2024 | Dec 31, 2024 | $6.67M | -37.8% |
| FY2023 | Dec 31, 2023 | $10.72M | -44.2% |
| FY2022 | Dec 31, 2022 | $19.19M | +70.3% |
| FY2021 | Dec 31, 2021 | $11.27M | +1469.9% |
| FY2020 | Dec 31, 2020 | $717.78K | +35.2% |
| FY2019 | Dec 31, 2019 | $530.80K | +11.2% |
| FY2018 | Dec 31, 2018 | $477.16K | +134.9% |
| FY2017 | Dec 31, 2017 | $203.15K | -37.0% |
| FY2016 | Dec 31, 2016 | $322.51K | +550.2% |
| FY2015 | Dec 31, 2015 | $49.60K | +5099.2% |
| FY2014 | Dec 31, 2014 | $954 | +155.1% |
| FY2013 | Dec 31, 2013 | $374 | -76.1% |
| FY2012 | Dec 31, 2012 | $1.57K | -49.5% |
| FY2011 | Dec 31, 2011 | $3.11K | +650.0% |
| FY2010 | Dec 31, 2010 | $414 | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $7.28M | +24.4% |
| Q2 FY2026 | Jun 30, 2026 | $9.38M | +32.0% |
| Q1 FY2026 | Mar 31, 2026 | $6.44M | -22.8% |
| Q4 FY2025 | Dec 31, 2025 | $7.81M | +17.1% |
| Q3 FY2025 | Sep 30, 2025 | $5.85M | -15.0% |
| Q2 FY2025 | Jun 30, 2025 | $7.11M | -11.1% |
| Q1 FY2025 | Mar 31, 2025 | $8.35M | -13.2% |
| Q4 FY2024 | Dec 31, 2024 | $6.67M | -37.8% |
| Q3 FY2024 | Sep 30, 2024 | $6.89M | -45.0% |
| Q2 FY2024 | Jun 30, 2024 | $7.99M | -43.4% |
| Q1 FY2024 | Mar 31, 2024 | $9.62M | -36.8% |
| Q4 FY2023 | Dec 31, 2023 | $10.72M | -44.2% |
| Q3 FY2023 | Sep 30, 2023 | $12.51M | -44.3% |
| Q2 FY2023 | Jun 30, 2023 | $14.13M | -39.7% |
| Q1 FY2023 | Mar 31, 2023 | $15.23M | +56.5% |
| Q4 FY2022 | Dec 31, 2022 | $19.19M | +70.3% |
| Q3 FY2022 | Sep 30, 2022 | $22.47M | +617.4% |
| Q2 FY2022 | Jun 30, 2022 | $23.43M | +3100.0% |
| Q1 FY2022 | Mar 31, 2022 | $9.73M | +1016.4% |
| Q4 FY2021 | Dec 31, 2021 | $11.27M | +1469.9% |
| Q3 FY2021 | Sep 30, 2021 | $3.13M | +636.5% |
| Q2 FY2021 | Jun 30, 2021 | $732.31K | +65.3% |
| Q1 FY2021 | Mar 31, 2021 | $871.88K | +85.8% |
| Q4 FY2020 | Dec 31, 2020 | $717.78K | +35.2% |
| Q3 FY2020 | Sep 30, 2020 | $425.24K | +28.7% |
| Q2 FY2020 | Jun 30, 2020 | $442.93K | +23.7% |
| Q1 FY2020 | Mar 31, 2020 | $469.31K | -18.8% |
| Q4 FY2019 | Dec 31, 2019 | $530.80K | +11.2% |
| Q3 FY2019 | Sep 30, 2019 | $330.38K | -7.1% |
| Q2 FY2019 | Jun 30, 2019 | $358.05K | +28.2% |
| Q1 FY2019 | Mar 31, 2019 | $577.86K | +98.4% |
| Q4 FY2018 | Dec 31, 2018 | $477.16K | +134.9% |
| Q3 FY2018 | Sep 30, 2018 | $355.62K | +68.4% |
| Q2 FY2018 | Jun 30, 2018 | $279.38K | -6.8% |
| Q1 FY2018 | Mar 31, 2018 | $291.27K | +48.5% |
| Q4 FY2017 | Dec 31, 2017 | $203.15K | -37.0% |
| Q3 FY2017 | Sep 30, 2017 | $211.15K | – |
| Q2 FY2017 | Jun 30, 2017 | $299.62K | – |
| Q1 FY2017 | Mar 31, 2017 | $196.13K | – |
| Q4 FY2016 | Dec 31, 2016 | $322.51K | – |
See a number that looks wrong?